Have you used ribociclib (Kisqali) during treatment for secondary (metastatic) breast cancer?

Hi everyone,

The Policy and Campaigns team at Breast Cancer Care are looking to hear from women who have experience of receiving ribociclib (Kisqali) during treatment for secondary (metastatic) breast cancer. Please find the details below.

Have you used ribociclib (Kisqali) during treatment for secondary (metastatic) breast cancer?

If so, we would very much like to hear of your experience of receiving this medicine. 

Why are we asking for your feedback?

Ribociclib (brand name Kisqali), is used to treat postmenopausal women with HR+, HER2- locally advanced or metastatic breast cancer who are previously untreated for their metastatic disease. 

The Scottish Medicines Consortium (SMC) is currently assessing ribociclib to decide whether or not to recommend it for routine availability on the NHS in Scotland. Breast Cancer Care Scotland has been asked to contribute to the SMC’s Patient and Clinician Engagement (PACE) process as part of this assessment.

We are now gathering evidence as part of the process and would like to hear from you if you, or someone you know, has been/is being treated with ribociclib.

You don’t have to be from Scotland to take part, in fact it doesn’t matter where you are from; the important thing is for us to collect as many patient views as possible. Your answers will be collated and presented to the SMC.

 Any quotes or information you supply will used anonymously in our evidence.

 The questions we would like your feedback on are:

  • How does your condition affect you on a daily basis?
  • Has ribociclib improved your quality of life and experience of care, and if so, how?
  • What has been the impact on your family or carers as a result of you using ribociclib?
  • Are there any disadvantages of ribociclib and how have these affected you?
  • Is there anything else you would wish to say about this medicine or the current availability of treatments for metastatic breast cancer?

If you wish to reply privately, please send any responses directly toemma.lavelle@breastcancercare.org.uk.

The deadline for contributions is 27 November.

Thank you

Helena at Breast Cancer Care